Back to Search
Start Over
Experts Puzzled and Troubled by F.D.A. Approval of Covid-19 Drug
- Source :
- The New York Times. October 30, 2020, B7
- Publication Year :
- 2020
-
Abstract
- Gilead Sciences said Wednesday that remdesivir, which has been authorized for emergency use since the spring, brought in $873 million in revenues so far this year. The United States reached [...]
- Subjects :
- United States. Food and Drug Administration -- Powers and duties
Gilead Sciences Inc. -- Company sales and earnings -- Product development -- Licensing, certification and accreditation -- Laws, regulations and rules
Biological products industry -- Company sales and earnings -- Product development -- Licensing, certification and accreditation
Drug approval -- Laws, regulations and rules
Government regulation
Company earnings/profit
General interest
News, opinion and commentary
Veklury (Medication) -- Product development
Subjects
Details
- Language :
- English
- ISSN :
- 03624331
- Database :
- Gale General OneFile
- Journal :
- The New York Times
- Publication Type :
- News
- Accession number :
- edsgcl.639871330